VC-Focused Group Says More Voices Better In Pushing FDA Reform

Reuters Life sciences investors and companies say the agency's approval process is too burdensome and is keeping good products away from the public. Venture capital investors and the companies they support closely watch what's happening at the U.S. Food and Drug Administration, the agency companies must navigate to get their drugs and devices approved for commercialization. They do more than...